HM10660A, a long-acting hIFN-α-2b, is a potent candidate for the treatment of hepatitis C through an enhanced biological half-life.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  International journal of pharmaceutics

• Publication date

  2017-12-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijpharm.2017.09.074PMID 28982547
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases.

  2013cited by this paper
• Peginterferon-α-2a (40kD)

  2012cited by this paper
• Alternative glycosylation modulates function of IgG and other proteins - implications on evolution and disease.

  2012cited by this paper
• Advances in the assessment and control of the effector functions of therapeutic antibodies

  2011cited by this paper
• Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR

  2010cited by this paper
• Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-α Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys

  2010cited by this paper
• Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates

  2009cited by this paper
• Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action.

  2009cited by this paper
• Glycosylation as a strategy to improve antibody-based therapeutics

  2009cited by this paper
• Clinical uses of interferons.

  2008cited by this paper
• Monoclonal Antibody Clearance

  2007cited by this paper
• FcRn: the neonatal Fc receptor comes of age

  2007cited by this paper
• Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.

  2006cited by this paper
• Antibody pharmacokinetics and pharmacodynamics.

  2004cited by this paper
• Pegylating IFNs at His-34 Improves the in Vitro Antiviral Activity Through the JAK/STAT Pathway

  2004cited by this paper
• The Development of a Modified Human IFN-α2b Linked to the Fc Portion of Human IgG1 as a Novel Potential Therapeutic for the Treatment of Hepatitis C Virus Infection

  2004cited by this paper
• Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys

  2002cited by this paper
• Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

  2001cited by this paper
• Structural and Biologic Characterization of Pegylated Recombinant IFN-α2b

  2001cited by this paper
• Structural and biologic characterization of pegylated recombinant IFN-alpha2b.

  2001cited by this paper
• Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

  2001cited by this paper
• Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

  2001cited by this paper
• Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data

  2000cited by this paper
• Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

  2000cited by this paper
• High level expression and secretion of Fc-X fusion proteins in mammalian cells.

  1998cited by this paper
• Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.

  1998cited by this paper
• Polyethylene glycol-conjugated pharmaceutical proteins

  1998cited by this paper
• Molecular cloning and characterization of two related and interferon-induced 56-kDa and 30-kDa proteins highly similar to 2'-5' oligoadenylate synthetase.

  1998cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C

  1998cited by this paper
• Effects of interferon‐alpha (IFN‐α) administration on leucocytes in healthy humans

  1997cited by this paper
• Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation.

  1995cited by this paper
• The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region

  1991cited by this paper
• Interferon-Induced and Double-Stranded RNA-Activated Enzymes: A Specific Protein Kinase and 2′,5′-Oligoadenylate Synthetases

  1991cited by this paper

• Preparation, characterization, and pharmacological study of a novel long-acting FGF21 with a potential therapeutic effect in obesity.

  2020cites this paper